Načítá se...
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with ov...
Uloženo v:
| Vydáno v: | Nephrol Dial Transplant |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6993197/ https://ncbi.nlm.nih.gov/pubmed/32003834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfz237 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|